CBD Reversed More Than 75% of Alzheimer's-Related Molecular Changes in Mice

RNA sequencing identified over 1,000 differentially expressed markers of Alzheimer's disease onset in mice. CBD treatment (80-100 mg/kg/day for 2 months) either eliminated or reversed the expression direction of more than 75% of these markers, spanning pathways including synaptic development, neurovascular interactions, mitochondrial function, and immunity.

Male 3xTg-AD mice and wild-type controls received daily dietary CBD (80-100 mg/kg/day) from 4.5 to 6.5 months of age. Researchers used RNA sequencing on blood and brain samples, metabolomics on brain regions, and behavioral assessments.

Most Alzheimer's treatments target one or two pathways. This study suggests CBD simultaneously affects dozens of pathways involved in disease onset, from inflammation and oxidative stress to synaptic plasticity and lipid metabolism, a breadth of action that single-target drugs cannot match.

Alzheimer's disease involves a cascade of interconnected molecular failures. The finding that CBD addresses more than 75% of these simultaneously in mice is remarkable, though the gap between mouse models and human Alzheimer's disease remains enormous.

Mouse model (3xTg-AD) does not fully replicate human Alzheimer's, male mice only, high CBD dose relative to human equivalents, treatment started before full disease development, no long-term follow-up beyond 2 months